William Blair downgraded Alector, Inc. (NASDAQ:ALEC) from "Outperform" to "Market Perform" following a failed drug trial.The company's stock price has significantly declined, currently standing at $3.21, after the announcement of the trial's failure.Alector's market capitalization is approximately $324.9 million, with a trading volume of 1,393,229 shares on the NASDAQ.Alector, Inc. (NASDAQ:ALEC) is a biotechnology company focused on developing therapies for neurodegenerative diseases. The company aims to ha ...